18^th World Hematology Congress

Hematopoietic Malignancies

Hematopoietic cancers are dealt with tumours of immune system cells. Most of them are encompassed of cells that are functionally heterogeneous with only a subdivision being in charge for tumor care. Leukemias are “liquid tumors” in the blood and are derived from the transformation of either a hematopoietic precursor in the bone marrow or a mature hematopoietic cell in the blood. Leukemias can be lymphoid or myeloid, and acute or chronic.

Most hematopoietic malignancies are comprised of cells that are functionally heterogeneous with only a subset being responsible for tumor maintenance.

The thorough perceptive of accumulation of genetic/epigenetic event progressions could prime to development of therapeutics that more effectively treat hematopoietic malignancies and potentially other cancers.

Hematopoietic cancers (HCs) are malignancies of immune system cells, associated with gross chromosomal abnormalities such as translocations.

Improvements in diagnosis and therapy, including hematopoietic stem cell transplantation and molecularly targeted strategies, have increased patient survival.